You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 7,622,115

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,622,115

Title:	Treatment with anti-VEGF antibodies
Abstract:	This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Inventor(s):	Fyfe; Gwendolyn (San Francisco, CA), Holmgren; Eric (Palo Alto, CA), Mass; Robert D. (Mill Valley, CA), Novotny; William (Foster City, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	11/763,263
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,622,115
Patent Claims:	1. A method for treating cancer in a patient comprising administering an effective amount of bevacizumab and assessing the patient for gastrointestinal perforation during treatment with bevacizumab. 2. The method of claim 1, wherein the cancer is colorectal cancer, rectal cancer, breast cancer, non-small cell lung cancer, renal cancer, prostate cancer, non-Hodgkin's lymphoma, liver cancer, pancreatic cancer, soft-tissue sarcoma, Kaposi's sarcoma, carcinoid carcinoma, head and neck cancer, melanoma, ovarian cancer, mesothelioma, multiple myeloma or glioblastoma. 3. The method of claim 1, wherein the method further comprises administering a chemotherapeutic agent. 4. The method of claim 3, wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folio acid analogs, pyrimidine analogs, purine analogs, vinca alkaloids, epipodophyllotoxins, antibiotics, L-Asparaginase, topoisomerase inhibitor, interferons, platinum coordination complexes, anthracenedione substituted urea, methyl hydrazine derivatives, adrenocortical suppressant, adrenocorticosteroids, progestins, estrogens, antiestrogen, androgens, antiandrogen, and gonadotropin-releasing hormone analog. 5. The method of claim 1, wherein the bevacizumab is administered to the patient at about 5-15 mg/kg every 2-3 weeks.

Details for Patent 7,622,115

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2023-05-30
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2023-05-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.